BlackRock Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History

BlackRock Advisors’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$3.17M	Sell	45,057 -300,086	-87%	-$21.3M	﹤0.01%	1312
2016 Q3	$24.5M	Buy	345,143 +2,114	+0.6%	+$135K	0.03%	452
2016 Q2	$16.8M	Buy	343,029 +1,147	+0.3%	+$74.2K	0.02%	587
2016 Q1	$21.6M	Sell	341,882 -218,512	-39%	-$14.3M	0.02%	522
2015 Q4	$62.9M	Sell	560,394 -13,820	-2%	-$1.38M	0.07%	277
2015 Q3	$55.3M	Buy	574,214 +108,177	+23%	+$12.4M	0.06%	283
2015 Q2	$47.7M	Buy	466,037 +18,881	+4%	+$1.47M	0.05%	313
2015 Q1	$27.8M	Buy	447,156 +13,048	+3%	+$725K	0.03%	458
2014 Q4	$19M	Sell	434,108 -2,545	-0.6%	-$117K	0.02%	566
2014 Q3	$24.7M	Buy	436,653 +410,015	+1,539%	+$20.6M	0.02%	515
2014 Q2	$1.2M	Sell	26,638 -63,584	-70%	-$2.62M	﹤0.01%	1389
2014 Q1	$4.41M	Buy	+90,222	New	+$4.64M	﹤0.01%	996

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock Advisors's RARE Position: Q4 2016 in Review

BlackRock Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 87% in Q4 2016, selling an estimated $21.3M and leaving 45,057 shares worth $3.17M. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

BlackRock Advisors first reported a position in RARE in Q1 2014 and has held it in 12 quarters since. The position peaked at $62.9M in Q4 2015. 174 funds tracked by Wall St. Rank hold RARE as of Q4 2016.

BlackRock Advisors held 45,057 shares of Ultragenyx Pharmaceutical worth $3.17M as of Q4 2016.
BlackRock Advisors sold 300,086 Ultragenyx Pharmaceutical shares in Q4 2016, an estimated $21.3M.
Ultragenyx Pharmaceutical made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #1312 holding.
BlackRock Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 12 quarters since.
BlackRock Advisors's Ultragenyx Pharmaceutical position peaked at $62.9M in Q4 2015.
174 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.